Liposomal Cytarabine This page contains brief information about liposomal cytarabine and links to more information from the National Cancer Institute (NCI), the Food and Drug Administration (FDA), and the National Library of Medicine (NLM). US Brand Name(s): | ![](https://webarchive.library.unt.edu/web/20090114173631im_/http://www.cancer.gov/images/spacer.gif) | DepoCyt | ![](https://webarchive.library.unt.edu/web/20090114173631im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/web/20090114173631im_/http://www.cancer.gov/images/spacer.gif) | FDA Approved: | ![](https://webarchive.library.unt.edu/web/20090114173631im_/http://www.cancer.gov/images/spacer.gif) | Yes |
Liposomal cytarabine is approved by the Food and Drug Administration (FDA) to be given as intrathecal therapy to treat lymphomatous meningitis (lymphoma that has spread to the meninges). Liposomal cytarabine is being studied in the treatment of other types of cancer.
Liposomal cytarabine is a form of cytarabine contained inside liposomes (very tiny particles of fat). This form may work better than other forms of cytarabine and have fewer side effects. Also, because its effects last longer in the body, it doesn't need to be given as often. For more information about cytarabine that may apply to liposomal cytarabine, see the Drug Information Summary for Cytarabine. Information from the NCIDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. Information from the NLM
MedlinePlus Information on Cytarabine - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This NLM patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied. Clinical TrialsClinical Trials for Liposomal Cytarabine - Check for trials from NCI's PDQ Cancer Clinical Trials Registry now accepting patients.
Important: The drug information on this Web page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top |